ANGPTL3 and homozygous familial hypercholesterolemia: Our principal finding was that in patients with HoFH receiving the best standard of care including lipoprotein apheresis, ANGPTL3 inhibition with evinacumab was effective in lowering the LDL-C concentration and was well tolerated over a period of 24 months.